Quote:

---

Therefore Leronlimab, a CCR5 antagonist being able to bind to gp120 will block cell-binding capabilities and, arguably, help the host to fight the disease.

---

Think of gp120 as a glue it firsts binds to CD4, then changes another gp120 spike to conform to the molecular shape of CCR5. With leronlimab attached it can't attach to the CCR5 receptor and inject its DNA. However the coronavirus use receptors other than CCR5, so whether CCR5 is blocked makes no difference in fighting the virus directly.

However it can fight on the secondary level on two fronts, reduction of the inflammation which is often the cause of death and with macrophage differentiation it should be able to boost the immune response.